BCAB Earnings — BioAtla, Inc. Common Stock Post-ER Performance | BigEarnings
BCAB — BioAtla, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$3.93
Market Cap$6.5M
P/E—
52W Range$3.26 – $71.50
Next Earnings2026-08-06
About BioAtla, Inc. Common Stock
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
